Literature DB >> 22065775

Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Anastasia R Goloudina1, Kan Tanoue, Arlette Hammann, Eric Fourmaux, Xavier Le Guezennec, Dmitry V Bulavin, Sharlyn J Mazur, Ettore Appella, Carmen Garrido, Oleg N Demidov.   

Abstract

The inactivation of the p53 tumor suppressor pathway in many cancers often increases their resistance to anticancer therapy. Here we show that a previously proposed strategy directed to Wip1 inhibition could be ineffective in tumors lacking p53. On the contrary, Wip1 overexpression sensitized these tumors to chemotherapeutic agents. This effect was mediated through interaction between Wip1 and RUNX2 that resulted, in response to anticancer treatment, in RUNX2-dependent transcriptional induction of the proapoptotic Bax protein. The potentiating effects of Wip1 overexpression on chemotherapeutic agents were directed only to tumor cells lacking p53. The overexpression of Wip1 in normal tissues provided protection from cisplatin-induced apoptosis through decreased strength of upstream signaling to p53. Thus, Wip1 phosphatase promotes apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065775      PMCID: PMC3258624          DOI: 10.1073/pnas.1107017108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

1.  Wip1 phosphatase modulates ATM-dependent signaling pathways.

Authors:  Sathyavageeswaran Shreeram; Oleg N Demidov; Weng Kee Hee; Hiroshi Yamaguchi; Nobuyuki Onishi; Calvina Kek; Oleg N Timofeev; Crissy Dudgeon; Albert J Fornace; Carl W Anderson; Yasuhiro Minami; Ettore Appella; Dmitry V Bulavin
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

Review 2.  Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation.

Authors:  Suk-Chul Bae; Yong Hee Lee
Journal:  Gene       Date:  2005-12-01       Impact factor: 3.688

3.  Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.

Authors:  Anastasia R Demidova; Mei Yee Aau; Li Zhuang; Qiang Yu
Journal:  J Biol Chem       Date:  2008-12-07       Impact factor: 5.157

Review 4.  Regulation of p53 downstream genes.

Authors:  W S el-Deiry
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

5.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

6.  Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action.

Authors:  D L Brautigan; M Brown; S Grindrod; G Chinigo; A Kruszewski; S M Lukasik; J H Bushweller; M Horal; S Keller; S Tamura; D B Heimark; J Price; A N Larner; J Larner
Journal:  Biochemistry       Date:  2005-08-23       Impact factor: 3.162

7.  Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor.

Authors:  Chunxi Ge; Guozhi Xiao; Di Jiang; Qian Yang; Nan E Hatch; Hernan Roca; Renny T Franceschi
Journal:  J Biol Chem       Date:  2009-09-30       Impact factor: 5.157

Review 8.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

9.  PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.

Authors:  David S P Tan; Maryou B K Lambros; Sydonia Rayter; Rachael Natrajan; Radost Vatcheva; Qiong Gao; Caterina Marchiò; Felipe C Geyer; Kay Savage; Suzanne Parry; Kerry Fenwick; Narinder Tamber; Alan Mackay; Tim Dexter; Charles Jameson; W Glenn McCluggage; Alistair Williams; Ashley Graham; Dana Faratian; Mona El-Bahrawy; Adam J Paige; Hani Gabra; Martin E Gore; Marketa Zvelebil; Christopher J Lord; Stanley B Kaye; Alan Ashworth; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

10.  A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Authors:  S Rayter; R Elliott; J Travers; M G Rowlands; T B Richardson; K Boxall; K Jones; S Linardopoulos; P Workman; W Aherne; C J Lord; A Ashworth
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

View more
  28 in total

1.  Role of wild-type p53-induced phosphatase 1 in cancer.

Authors:  Zhi-Peng Wang; Ye Tian; Jun Lin
Journal:  Oncol Lett       Date:  2017-07-27       Impact factor: 2.967

2.  Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer.

Authors:  Ling Wang; Adam J Mosel; Gregory G Oakley; Aimin Peng
Journal:  Mol Cancer Ther       Date:  2012-09-12       Impact factor: 6.261

Review 3.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

4.  Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratio.

Authors:  Anastasia R Goloudina; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

5.  WIP1 regulates the proliferation and invasion of nasopharyngeal carcinoma in vitro.

Authors:  Yongquan Zhang; Hong Sun; Guangxiang He; An Liu; Fengjun Wang; Lu Wang
Journal:  Tumour Biol       Date:  2014-05-07

6.  MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.

Authors:  Jing Xie; Fei Yu; Dan Li; Xuchao Zhu; Xiaoping Zhang; Zhongwei Lv
Journal:  Tumour Biol       Date:  2015-08-18

7.  Oncogenic WIP1 phosphatase attenuates the DNA damage response and sensitizes p53 mutant Jurkat cells to apoptosis.

Authors:  Mehtap Kilic Eren; Nur Betül Kartal; Hatice Pilevneli
Journal:  Oncol Lett       Date:  2021-04-19       Impact factor: 2.967

8.  Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells.

Authors:  N Heidari; A V Miller; M A Hicks; C B Marking; H Harada
Journal:  Cell Death Dis       Date:  2012-07-19       Impact factor: 8.469

9.  Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.

Authors:  G Browne; H Nesbitt; L Ming; G S Stein; J B Lian; S R McKeown; J Worthington
Journal:  Br J Cancer       Date:  2012-10-16       Impact factor: 7.640

10.  Generation of the tumor-suppressive secretome from tumor cells.

Authors:  Shengzhi Liu; Xun Sun; Kexin Li; Rongrong Zha; Yan Feng; Tomohiko Sano; Chuanpeng Dong; Yunlong Liu; Uma K Aryal; Akihiro Sudo; Bai-Yan Li; Hiroki Yokota
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.